TheraBionic

DEVICE2 trials

Sponsors

Wake Forest University Health Sciences, THERABIONIC INC.

Conditions

Hepatocellular CarcinomaMetastatic AdenocarcinomaPancreatic Cancer

Phase 2

Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib

TerminatedNCT04327700

Wake Forest University Health SciencesHepatocellular Carcinoma

Start: 2021-01-26End: 2024-05-31Updated: 2026-03-05

Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer

RecruitingNCT05776524

THERABIONIC INC.Metastatic Adenocarcinoma, Pancreatic Cancer

Start: 2023-06-13End: 2029-07-31Target: 46Updated: 2025-03-25

Related Papers

A phase 2 study of amplitude-modulated radiofrequency electromagnetic fields (AM RF EMF) in metastatic pancreatic cancer.

Journal of Clinical Oncology2025-01-27

Sequential neoadjuvant chemotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.

Journal of Clinical Oncology2024-06-01